Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome
NCT06681012Recruiting
- Sponsor
- Devintec Pharma
- Start
- Oct 2024
- Primary completion
- Jul 2027
- Countries
- 4
01
Overview
Randomised, double-blind trial in irritable bowel syndrome (IBS) (2 arms), sponsored by Devintec Pharma. Primary endpoint: Composite response rate for abdominal pain and stool consistency at 8 weeks. Started Oct 2024; status: recruiting.
02
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT06681012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06681012.